Francesca Fontana

speaker

586 appearances 22 recordings 1 series first heard Feb 2025 last heard 10 Jan

Francesca Fontana’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 9 in all, peaking in Dec 2025 with 3.

Appearances

newest first · ▶ plays the moment

WSJ What’s News · What’s News in Markets: Defense Stocks Rise, Beer Beats, Pharma Deal · 10 Jan 2026 podcast

And earlier in the week, Lockheed Martin said it would more than triple Patriot missile production after reaching a seven-year deal with the Pentagon.

Lockheed shares ended up gaining about 2% Tuesday and notched a weekly gain of 9.2%.

You may know the company better as the importer of Corona beer.

Dedicated listeners will recall that we've talked about this company's continued struggle with beer sales in recent quarters.

And this latest quarter wasn't much different.

Constellation reported lower sales and profit as customers, particularly Hispanic customers, continued to buy less beer.

In addition to the macro trends we've been hearing about from companies like weak consumer sentiment and a softening job market, Constellation also cited a downturn in, quote, 4,000-calorie jobs, a.k.a.

physically demanding jobs in areas like construction or mining that typically boost beer sales.

So the results released after the market close on Wednesday weren't great, but they were better than Wall Street was expecting.

Shares closed 5.3 percent higher on Thursday.

And on the week, they added 4.1%.

Finally, we have a big pharma deal to talk about.

Eli Lilly said Wednesday that it agreed to pay around $1 billion for drug maker Ventix Biosciences, a deal that could help Lilly compete in a promising new treatment area.

Usually, when we're talking about buzzy pharma news, it's all about weight loss drugs like Ozempic and the like.

But not today.

Not directly, at least.

Phentix has been focused on developing drugs targeting inflammatory response.

And if its experimental pills pan out, they would add to Lilly's portfolio of treatments for autoimmune conditions, as well as for obesity and other related disorders.

And it could help Lilly compete against other big rivals, including Ozempic maker Novo Nordisk, that analysts say have been circling this emerging category.

Ventix shares ended up soaring 37% Wednesday and on the week jumped a whopping 64%.

Showing 21–40 of 586 · page 2 of 30